Flea/Tick Prevention

Verify with FDA CVM →

23 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
23
Total Reports
1
Deaths Reported
430.0%
Death Rate

Active Ingredients

Flea/Tick Prevention

Administration Routes

UnknownTopicalOral

Species Affected

Dog 21
Cat 2

Most Affected Breeds

Retriever - Labrador 5
Domestic Shorthair 2
Dalmatian 2
Terrier (unspecified) 1
Terrier - Yorkshire 1
Terrier - Irish Soft-coated Wheaten 1
Spitz - American Eskimo Dog 1
Coonhound - Black and Tan 1
Siberian Husky 1
Terrier - Bull - American Pit 1

Most Reported Reactions

Vomiting 6
Diarrhoea 5
Lethargy (see also Central nervous system depression in 'Neurological') 4
Decreased appetite 3
INEFFECTIVE, LOSS OF EFFECT 2
Seizure NOS 2
Inappropriate urination 2
Crust 2
Weakness 2
Weight loss 2
Elevated serum alkaline phosphatase (SAP) 2
INEFFECTIVE, ATOPY CONTROL 2

Outcome Breakdown

Ongoing
10 (43.5%)
Outcome Unknown
8 (34.8%)
Recovered/Normal
4 (17.4%)
Died
1 (4.3%)

Data Summary

Metric Value
Total adverse event reports 23
Reports involving death 1
Case-fatality rate (reported events) 430.0%
Distinct species in reports 2
Distinct breeds in reports 17
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Flea/Tick Prevention Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 23 adverse event reports referencing Flea/Tick Prevention, including 1 reports in which the animal died — a 430.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Flea/Tick Prevention. Reported administration routes include Unknown, Topical, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Flea/Tick Prevention reports are Dog (21 reports), Cat (2 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (5), Domestic Shorthair (2), Dalmatian (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Flea/Tick Prevention are Vomiting (6), Diarrhoea (5), Lethargy (see also Central nervous system depression in 'Neurological') (4), Decreased appetite (3). Of the 23 reports with a coded outcome, Ongoing is the leading category at 43.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Flea/Tick Prevention.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial